A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo...

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Nephrology

Background:

• The cannabinoid CB2 receptor (CB2R) is a key target for inflammatory diseases and tissue injury.
• Effective in vivo studies require selective CB2R ligands with well-characterized pharmacokinetic properties.
• Existing CB2R ligands often lack sufficient pharmacokinetic data for in vivo applications.

Purpose of the Study:

• To develop and characterize a novel, potent, and selective CB2R agonist for in vivo research.
• To assess the pharmacokinetic profile and brain penetration of the novel compound.
• To evaluate the therapeutic potential of the compound in preclinical models of kidney injury.

Main Methods:

• Synthesis and in vitro characterization of a tetra-substituted pyrazole CB2R full agonist, RNB-61.
• Radioligand binding assays to determine affinity (Ki) and dissociation constants (Kd) for CB2R.
• In vivo pharmacokinetic studies, including assessment of P-glycoprotein-mediated efflux.
• Evaluation of RNB-61 in mouse ischemia-reperfusion acute kidney injury (AKI) and rat chronic kidney injury (CKI) models.

Main Results:

• RNB-61 demonstrated high potency (Ki 0.13-1.81 nM) and selectivity (>6,800-fold over CB1R) for CB2R.
• The compound exhibited peripherally restricted action due to P-glycoprotein efflux, limiting brain penetration.
• RNB-61 showed good oral bioavailability and suitable systemic pharmacokinetic properties.
• Dose-dependent nephroprotective and antifibrotic effects were observed in both AKI and CKI models.

Conclusions:

• RNB-61 is a highly potent and selective CB2R full agonist with advantageous pharmacokinetic properties for in vivo studies.
• Its peripherally restricted action and demonstrated efficacy in kidney injury models make it a valuable tool compound.
• RNB-61 represents an improvement over existing CB2R ligands for preclinical research in inflammatory and kidney diseases.